Stryker Corporation (SYK) Return on Invested Capital (ROIC): 8.53%
Is Stryker Corporation’s return on invested capital (ROIC) high or low?
Stryker Corporation's return on invested capital (ROIC) of 8.53% is 15% below its 5-year average of 10.08%, near the low end of its 5-year range (8.22%–11.75%).
As of Wednesday, June 17, 2026. 15.88% below its 12-month average of 10.14%.
SYK Return on Invested Capital (ROIC) Chart
SYK Average Return on Invested Capital (ROIC) Chart
SYK Current vs Average Return on Invested Capital (ROIC) Chart
SYK Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
8.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
10.14%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
10.34%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
10.08%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
10.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
11.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
12.54%
CURRENT VS TTM AVG
-15.88%
CURRENT VS 3Y AVG
-17.48%
CURRENT VS 5Y AVG
-15.35%
CURRENT VS 10Y AVG
-19.23%
CURRENT VS 15Y AVG
-23.57%
CURRENT VS 20Y AVG
-31.99%
SYK Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stryker Corporation (SYK) | $119.06B | 8.53% | 10.14% | 10.34% | 10.08% |
| Bristol-Myers Squibb Company (BMY)vs › | $114.38B | 13.90% | 13.75% | 11.92% | 10.17% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $113.82B | 18.12% | 10.38% | 14.75% | 17.51% |
| CVS Health Corporation (CVS)vs › | $127.54B | 4.72% | 4.17% | 4.46% | 4.93% |
| Danaher Corporation (DHR)vs › | $128.72B | 5.72% | 5.90% | 6.54% | 6.70% |
| Medtronic plc (MDT)vs › | $104.05B | 0.00% | 3.04% | 3.93% | 4.51% |
| Intuitive Surgical, Inc. (ISRG)vs › | $148.26B | 13.71% | 12.85% | 12.25% | 11.92% |
| Pfizer Inc. (PFE)vs › | $148.76B | 8.84% | 9.06% | 10.60% | 10.43% |
| HCA Healthcare, Inc. (HCA)vs › | $88.05B | 18.53% | 17.61% | 17.07% | 16.89% |
| Elevance Health Inc. (ELV)vs › | $86.74B | 6.65% | 6.70% | 7.11% | 7.33% |
Capital Efficiency
ROIC
8.5%
ROE
14.5%
Stryker Corporation Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Stryker Corporation Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The return on invested capital (ROIC) for SYK stock is 8.53%.
- Is Stryker Corporation's return on invested capital (ROIC) high or low?
- Stryker Corporation's return on invested capital (ROIC) of 8.53% is 15% below its 5-year average of 10.08%, near the low end of its 5-year range (8.22%–11.75%).
- What is the TTM average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The TTM average return on invested capital (ROIC) for SYK stock is 10.14%.
- What is the 3Y average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The 3Y average return on invested capital (ROIC) for SYK stock is 10.34%.
- What is the 5Y average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The 5Y average return on invested capital (ROIC) for SYK stock is 10.08%.
- What is the 10Y average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The 10Y average return on invested capital (ROIC) for SYK stock is 10.56%.
- What is the 15Y average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The 15Y average return on invested capital (ROIC) for SYK stock is 11.16%.
- What is the 20Y average return on invested capital (ROIC) for Stryker Corporation (SYK)?
- The 20Y average return on invested capital (ROIC) for SYK stock is 12.54%.
Stryker Corporation Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 8.53% |
| 2024-12-31 | 11.75% |
| 2023-12-31 | 10.78% |
| 2022-12-31 | 10.29% |
| 2021-12-31 | 10.89% |
| 2020-12-31 | 8.22% |
| 2019-12-31 | 10.31% |
| 2018-12-31 | 13.04% |
| 2017-12-31 | 7.01% |
| 2016-12-31 | 12.20% |
| 2015-12-31 | 13.15% |
| 2014-12-31 | 7.08% |
| 2013-12-31 | 13.29% |
| 2012-12-31 | 12.53% |
| 2011-12-31 | 14.86% |
| 2010-12-31 | 14.63% |
| 2009-12-31 | 15.37% |
| 2008-12-31 | 18.32% |
| 2007-12-31 | 15.83% |
| 2006-12-31 | 17.50% |
| 2005-12-31 | 17.81% |
| 2004-12-31 | 18.34% |
| 2003-12-31 | 20.42% |
| 2002-12-31 | 17.63% |
| 2001-12-31 | 16.71% |
| 2000-12-31 | 12.12% |
| 1999-12-31 | -3.82% |
| 1998-12-31 | 5.66% |
| 1997-12-31 | 15.61% |
| 1996-12-31 | 11.31% |
Related Metrics
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo